Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors

Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

Clin Cancer Res.

Maio M, Hamid O, Larkin J, Covre A, Altomonte M, Calabrò L, Vardana SA, Robert C, Ibrahim R, Anichini A, Wolchok JD, Di Giacomo AM

doi: 10.1158/1078-0432.CCR-20-1657.

Further Publications

Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors

Eur J Cancer.

Maillet D, Corbaux P, Stelmes JJ, Dalle S, Locatelli-Sanchez M, Perier-Muzet M, Duruisseaux M, Kiakouama-Maleka L, Freyer G, Boespflug A, Péron J

doi: 10.1016/j.ejca.2020.03.017.

COVID-19

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Lancet Oncol

Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, Domingo-Vila C, Hayday TS, Graham C, Seow J, Abdul-Jawad S, Kamdar S, Harvey-Jones E, Graham R, Cooper J, Khan M, Vidler J, Kakkassery H, Sinha S, Davis R, Dupont L, Francos Quijorna I, O'Brien-Gore C, Lee PL, Eum J, Conde Poole M, Joseph M, Davies D, Wu Y, Swampillai A, North BV, Montes A, Harries M, Rigg A, Spicer J, Malim MH, Fields P, Patten P, Di Rosa F, Papa S, Tree T, Doores KJ, Hayday AC, Irshad S

doi: 10.1016/S1470-2045(21)00213-8

COVID-19

Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines)

Cancer Treat Rev.

Slimano F, Baudouin A, Zerbit J, Toulemonde-Deldicque A, Thomas-Schoemann A, Chevrier R, Daouphars M, Madelaine I, Pourroy B, Tournamille JF, Astier A, Ranchon F, Cazin JL, Bardin C, Rioufol C

doi: 10.1016/j.ctrv.2020.102063.

Further Publications

Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study

Eur J Cancer

Da Silva Lopes AM, Colomer-Lahiguera S, Mederos Alfonso N, Aedo-Lopez V, Spurrier-Bernard G, Tolstrup LK, Pappot H, Aspeslagh S, Rogiers A, Neyns B, Haanen JB, Mitchell SA, Addeo A, Michielin O, Eicher M

doi: 10.1016/j.ejca.2021.08.026

Breast Cancer

Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium

Breast Cancer Res Treat.

Dietz JR, Moran MS, Isakoff SJ, Kurtzman SH, Willey SC, Burstein HJ, Bleicher RJ, Lyons JA, Sarantou T, Baron PL, Stevens RE, Boolbol SK, Anderson BO, Shulman LN, Gradishar WJ, Monticciolo DL, Plecha DM, Nelson H, Yao KA

doi: 10.1007/s10549-020-05644-z.

Further Publications

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer

JAMA Oncol.

Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, Fedrizzi S, Chrétien B, Da-Silva A, Plane AF, Legallois D, Milliez PU, Lelong-Boulouard V, Alexandre J

doi: 10.1001/jamaoncol.2020.0726.

Further Publications

Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

Eur J Cancer.

de Joode K, Dumoulin DW, Tol J, Westgeest HM, Beerepoot LV, van den Berkmortel FWPJ, Mutsaers PGNJ, van Diemen NGJ, Visser OJ, Oomen-de Hoop E, Bloemendal HJ, van Laarhoven HWM, Hendriks LEL, Haanen JBAG, de Vries EGE, Dingemans AC, van der Veldt AAM, DOCC Investigators.

doi: 10.1016/j.ejca.2020.09.027.

Radio-Oncology

Safety of Thoracic Radiotherapy in Patients with Prior Immune-Related Adverse Events from Immune Checkpoint Inhibitors

Ann Oncol.

Shaverdian N, Beattie J, Thor M, Offin M, Shepherd AF, Gelblum DY, Wu AJ, Simone CB 2nd, Hellmann MD, Chaft JE, Rimner A, Gomez DR

doi: 10.1016/j.annonc.2020.09.016.

Related content

Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines)

Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study

Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer

Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

Safety of Thoracic Radiotherapy in Patients with Prior Immune-Related Adverse Events from Immune Checkpoint Inhibitors